Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

Abstract Background Advanced or metastatic esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis; new first‐line systemic treatment options are needed. Combining immuno‐oncology therapies with standard chemotherapy may represent a promising approach for the treatment of solid t...

詳細記述

書誌詳細

出版年:	Cancer Medicine
主要な著者:	Dae Ho Lee, Hye Ryun Kim, Bhumsuk Keam, Ken Kato, Yasutoshi Kuboki, Haiyan Gao, Alejandro Yovine, Scott H. Robbins, Myung‐Ju Ahn
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2023-08-01
主題:	chemotherapy clinical trials esophageal squamous cell immunology
オンライン･アクセス:	https://doi.org/10.1002/cam4.6260